This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

reputable news agency


Study finds first-line biparametric MRI less cost-effective than PSA for prostate cancer screening

First-line biparametric MRI less cost-effective than PSA for prostate cancer screening

From an economic perspective, first-line prostate-specific antigen (PSA) testing is favored over biparametric magnetic resonance imaging (bpMRI) for prostate cancer screening, mainly due to false-positive results and overdiagnosis, according to a study published online June 4 in the Annals of Internal Medicine.

Roman Gulati, from the Fred Hutchinson Cancer Center in Seattle, and colleagues examined the and cost-effectiveness of first-line bpMRI versus PSA-based screening in a using a microsimulation model. The target population comprised U.S. men aged 55 years without prior screening or prostate cancer diagnosis.

The researchers found that first-line bpMRI versus PSA testing prevented two to three prostate cancer deaths and added 10 to 30 life-years per 1,000 men, but, depending on the biopsy imaging scheme, increased the number of biopsies by 1,506 to 4,174 and the number of over-diagnoses by 38 to 124.

The greatest net monetary benefits were seen for first-line PSA testing with multiparametric MRI followed by either biopsy approach for Prostate Imaging Reporting and Data System 4 to 5 at conventional cost-effectiveness thresholds. In sensitivity analysis, even if bpMRI was free, all men with low-risk prostate cancer underwent surveillance, and screening was quadrennial, first-line PSA still remained cost-effective.

"Our analyses suggest that the economic value of a first-line screening test, such as bpMRI, is driven by false-positive results and overdiagnoses rather than the cost of the test," the authors write. "Accordingly, our results suggest that screening efforts should focus on strategies that reduce false-positive results and over-diagnoses to improve ."

More information: Roman Gulati et al, Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer, Annals of Internal Medicine (2024). DOI: 10.7326/M23-1504

Daniel D. Joyce et al, The Cost-Effectiveness of Prostate Cancer Screening That Incorporates Magnetic Resonance Imaging, Annals of Internal Medicine (2024). DOI: 10.7326/M24-0878

Journal information: Annals of Internal Medicine

Copyright © 2024 HealthDay. All rights reserved.

Citation: Study finds first-line biparametric MRI less cost-effective than PSA for prostate cancer screening (2024, June 4) retrieved 18 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Prostate cancer screening: Longer screening intervals are safe with low baseline prostate-specific antigen


Feedback to editors